Business Wire

WA-ITRON

18.2.2021 14:47:08 CET | Business Wire | Press release

Share
Itron to Host First Itron Utility Week for Smart City and Utility Leaders in EMEA

Itron, Inc. (NASDAQ: ITRI), which is innovating the way utilities and cities manage energy and water, announced that it will host its flagship event, Itron Utility Week (IUW), virtually for smart city and utility leaders in Europe, Middle East and Africa (EMEA) on March 16 and 17, 2021. As the first regional IUW, the two-day event will bring leaders together virtually to share insights and solutions to address pressing challenges and create opportunity, together. To ensure the safety of all attendees in light of the COVID-19 pandemic, the customer-focused event will be completely virtual.

“We are thrilled to introduce this event to EMEA for the first time to bring together industry experts, colleagues and thought leaders to share fresh perspectives and open the door to endless possibilities through innovation,” said Marina Donovan, vice president of global marketing and public affairs at Itron. “For decades, Itron has collaborated with cities, municipalities and utilities in EMEA to provide innovative, long-term energy and water solutions. At IUW EMEA, we look forward to building on this success to create a more resourceful world.”

“This event has been designed to share knowledge and experience and discuss ways of solving issues facing utilities, municipalities and cities in EMEA,” said Andrew Jones, vice president of Sales for EMEA. “I look forward to gathering virtually with industry leaders, utility peers and smart city representatives to share ideas to create a brighter future for ourselves, our businesses and our communities.”

Itron Utility Week EMEA will be offered virtually and at no charge and will be available in English with subtitles in French, German, Spanish and Italian.

What:

 

Itron Utility Week EMEA 2021 includes peer-led breakout sessions about technology, trends and best practices; insightful keynotes from industry leaders; engaging and thought-provoking panels; and an interactive product showcase of select Itron solutions.

When:

 

March 16-17, 2021

Where:

 

Online

Sessions: Keynote and featured sessions at Itron Utility Week EMEA include:

  • Opening Keynote: Tom Deitrich, Itron’s CEO and president, will open the event with Andrew Jones, Itron’s vice president of Sales, to discuss how to deliver better ROI and empower business transformation for utilities and cities.
  • Breakout Sessions: Tailored breakout sessions provide the opportunity to learn from and have conversations with industry peers and Itron employees who have a firsthand understanding of the issues at play in the sector. Breakout sessions are organized into two tracks: Water Management and Smart City and Utility Solutions. Among the topics that will be covered are:
    • Leveraging multi-purpose networks to enable digital communities;
    • Reducing non-revenue water through leak detection;
    • Quantifying the value and benefits of distributed intelligence;
    • Accelerating electric vehicle adoption through grid analytics and charging management; and
    • A smart city panel where several city and community experts will share how cities are navigating the pandemic and how connected city infrastructure and services can aid recovery.

To keep up with live updates throughout the conference read updates on the Itron blog and follow Itron and #IUWEMEA on social media. There is no charge to attend and event registration is now open for Itron customers, prospects and partners. For more information about Itron Utility Week EMEA: Empowering Innovation, visit itron.com/iuwemea .

About Itron

Itron enables utilities and cities to safely, securely and reliably deliver critical infrastructure solutions to communities in more than 100 countries. Our portfolio of smart networks, software, services, meters and sensors helps our customers better manage electricity, gas and water resources for the people they serve. By working with our customers to ensure their success, we help improve the quality of life, ensure the safety and promote the well-being of millions of people around the globe. Itron is dedicated to creating a more resourceful world. Join us: www.itron.com .

Itron® is a registered trademark of Itron, Inc. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye